Clinical Scorecard: Musings from The Power List: Ali Tavassoli
At a Glance
| Category | Detail |
|---|---|
| Condition | Cyclic Peptides in Drug Discovery |
| Key Mechanisms | Intracellular screening of cyclic peptide libraries, macrocyclisation, N-methylation, intramolecular hydrogen bonding. |
| Target Population | Patients requiring novel therapeutics for previously difficult-to-target diseases. |
| Care Setting | Biopharma industry and drug development. |
Key Highlights
- Recognition by the Royal Society of Chemistry and the Medicine Maker Power List 2025.
- Expansion of druggable targets beyond traditional boundaries.
- Challenges in aligning scientific timelines with funding cycles.
- Emerging evidence supporting oral bioavailability of cyclic peptides.
- Need for diversified capital in biotech to support long-term drug development.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Mismatch between scientific timelines and funding cycles.
- Fragility of companies relying on single targets or markets.
Patient & Prescribing Data
Patients with diseases previously considered undruggable.
Cyclic peptides and targeted degraders are emerging as viable therapeutic options.
Clinical Best Practices
- Encourage longer-term partnerships between biotech and pharma.
- Implement pull incentives for areas of market failure.
- Diversify therapeutic modalities and geographic markets.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
